Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).
Phase 2
- Conditions
- Non Small Cell Lung Cancer
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Immunicom Inc
- Target Recruit Count
- 24
- Registration Number
- NCT04690686
- Locations
- 🇹🇷
Acibadem Atakent Hospital, Medical Oncology Department, Istanbul, Kucukcekmece, Turkey
🇹🇷Acibadem Maslak Hospital, Medical Oncology Department - coordinating site, Istanbul, Sariyer, Turkey
🇹🇷Acibadem Altunizade Hospital, Mecical Oncology Department, Istanbul, Uskudar, Turkey
A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients
Phase 1
- Conditions
- Advanced Breast Cancer
- Interventions
- Other: Plasma soluble TNF receptor pulldown + chemotherapyOther: Plasma soluble TNF receptor pulldownDrug: Chemotherapy Drugs, Cancer
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Immunicom Inc
- Target Recruit Count
- 170
- Registration Number
- NCT04004910
- Locations
- 🇵🇱
Katedra i Klinika Onkologii UJ CM, Kraków, Małopolskie, Poland
🇵🇱Centrum Medyczne INTERCOR Sp. z o.o., Bydgoszcz, Poland
🇵🇱Klinika Pneumonologii, Onkologii i Alergologii SPSK Nr 4 w Lublinie, Lublin, Poland
News
No news found